头颈部鳞癌发病机制是一个多阶段演变的过程,包括正常鳞状上皮基因突变、信号传导通路激活等,可导致增生、良性肿瘤、原位癌及恶变。其中,表皮生长因子受体(EGFR)扮演着重要的角色。因此,有望通过阻滞EGFR所激活的信号通路,来控制头颈部恶性肿瘤的发展。目前这方面的研究进展较快,其中Cetuximab是研究的重点之一。为此,就近年来关于Cetuximab在头颈部癌中的应用做一综述。1 EGFR在头颈部鳞癌发生中的作用近20年来,大部分研究报遭了头颈部鳞癌EGFR呈现 Head and neck squamous cell carcinoma is a multi-stage evolution of the pathogenesis, including normal squamous epithelial gene mutations, signal transduction pathway activation, can lead to proliferation, benign tumors, carcinoma in situ and malignant transformation. Among them, epidermal growth factor receptor (EGFR) plays an important role. Therefore, it is expected to control the development of head and neck malignant tumors by blocking the signaling pathway activated by EGFR. At present, the research in this area is progressing rapidly, among which Cetuximab is one of the focuses of research. To this end, in recent years on Cetuximab in the application of head and neck cancer are reviewed. 1 EGFR in the occurrence of head and neck squamous cell carcinoma in the past 20 years, most studies have been reported EGFR of head and neck squamous cell carcinoma